Abstract:

Breast cancer has become the most common type of cancer in the world, harming the majority of women's physical and mental health and challenging clinical prevention and treatment of tumors. With the in-depth research on the pathogenesis and metastasis mechanism of breast cancer, as well as the development of translational research such as multiomics technology and tumor immunity, it has been proved that breast cancer has highly heterogeneous molecular and clinical characteristics. The clinical treatment methods of different subtypes of breast cancer are different and related, and the achievements in the field of breast cancer clinical research are fruitful. In 2022, results of important clinical trials have achieved for different subtypes of breast cancer. For the neo-adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer, the PHEDRA study provided new adjuvant treatment options for HER2 positive breast cancer patients; And for the HER2 positive metastatic breast cancer, PHILA study and SYSUCC-002 study results provided reference for clinicians. For patients with brain metastasis, PERMEATE study showed that pyrrolitinib combined with capecitabine regimen was to become the preferred treatment scheme for HER2 positive brain metastasis population, especially for patients with brain metastasis without local radiotherapy. In hormone receptor positive breast cancer, a number of clinical trials (monarchE study, DAWNA-1 study, MONALEESA series of studies, etc.) of arbacilli, daracilli, rebosilli and others reported their efficacy on visceral metastasis. For triple-negative breast cancer, many clinical trials are under way. This paper aimed to review the recent advances in clinical research on breast cancer in the past year.

Key words: Breast cancer, Clinical trials, Important achievements, Human epidermal growth factor receptor 2, Hormone receptor, Triple-negative breast cancer, Targeted therapy, Chemotherapy, Combination therapy, Immunotherapy